| Home > In process > Genetisch informierte Therapie in der Psychiatrie: neue Dynamik durch APOE und Antikörpertherapie der Alzheimer-Krankheit | Genetically informed treatment in psychiatry: new dynamics through APOE and antibody treatment of Alzheimer's disease |
| Journal Article (Review Article) | DZNE-2026-00075 |
; ; ; ; ; ; ; ;
2026
Springer
Heidelberg
This record in other databases:
Please use a persistent id in citations: doi:10.1007/s00115-025-01839-1
Abstract: The European Medicines Agency has recommended testing for the ApoE-genotype prior to treatment of Alzheimer's disease with Lecanemab. The drug approval is limited to patients who are not homozygous for the ApoE epsilon 4 allele. This is to reduce the risk of undesired adverse effects in the patients treated with Lecanemab. With this recommendation for the first time a psychiatric therapy will be genetically informed.
Keyword(s): Alzheimer Disease: genetics (MeSH) ; Alzheimer Disease: drug therapy (MeSH) ; Alzheimer Disease: diagnosis (MeSH) ; Humans (MeSH) ; Antibodies, Monoclonal, Humanized: therapeutic use (MeSH) ; Antibodies, Monoclonal, Humanized: adverse effects (MeSH) ; Genetic Testing: methods (MeSH) ; Genetic Predisposition to Disease: genetics (MeSH) ; Apolipoproteins E: genetics (MeSH) ; ApoE-genotype ; Adverse effects ; Alzheimer disease ; Lecanemab ; Medication safety ; Antibodies, Monoclonal, Humanized ; Apolipoproteins E
|
The record appears in these collections: |